Sponsored by:
Viral Hepatitis Grand Rounds
from the Perelman School of Medicine at the
University of Pennsylvania
Academic Year 2013-2014
“Novel Approaches for the Treatment of HIV/HCV Co-Infection "
February 5, 2014
12:00 PM (EDT) - 1:00 PM (EDT)
BRB II/III Auditorium
David L. Thomas, MD, MPH
Professor of Medicine
Director, Division of Infectious Diseases
Johns Hopkins School of Medicine
Baltimore, Maryland
Target Audience
This program has been designed for departmental/institutional faculty, fellows, residents, medical students, nurses,
nurse practitioners, physician assistants and allied health professionals in the medical specialties of infectious disease,
hepatology, gastroenterology, and internal medicine
Educational Objectives
After completing this activity, participants should be able to:
 Demonstrate increased understanding of the epidemiology of and risk factors for viral hepatitis.

Increase the rate of testing for viruses associated with hepatitis.

Demonstrate improved knowledge, competence and clinical practice in terms of the current standards and
guidelines for the management of patients with viral hepatitis.

Demonstrate an improved understanding of the treatment of viral hepatitis in patient co-infected with HIV or
other viral infections.
Accreditation
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA
PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
Acknowledgement of Commercial Support*
AbbVie Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Therapeutics, Gilead Sciences Medical Affairs and
Vertex Pharmaceuticals
For more information, please contact
Richard Gordon
847-951-5318
rgorgdon@viraled.com
Check your CME online at www.penncmeonline.com
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to
control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with
any commercial interest that provides products or services that may be relevant to the content of this continuing medical
education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial
relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from
involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in
improving medical practice, are based on valid content, and are independent of control from commercial interests and free of
commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information
provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic
of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based
presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic, Director
of CME and the peer reviewer Zalman Agus, MD, Associate Dean for CME, have disclosed that they have no relevant
financial relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests
related to the content of this educational activity:
PLANNING COMMITTEE MEMBER NAME
BRIAN BOYLE, MD
RICK GORDON
OLIVER FULTZ
PRESENTER NAME
David L. Thomas, MD, MPH
The following individuals have reported the listed relevant financial relationships with commercial interests related to the content of this
educational activity.
PLANNING COMMITTEE MEMBER NAME
NAME OF COMMERCIAL INTEREST
RELATIONSHIP
K. RAJENDER REDDY, MD
GENENTECH-ROCHE, MERCK,ABBVIE, BMS, VERTEX
ADVISORY BOARD
JANSSEN, IDENIX, NOVARTIS, GILEAD
ADVISORY BOARD
GENENTECH-ROCHE, MERCK, ABBVIE, BMS, VERTEX, JANSSEN, GILEAD
RESEARCH SUPPORT
DAVID KAPLAN, MD
MERCK INVESTIGATOR STUDIES PROGRAM, BAYER PHARMA
RESEARCH GRANT
MARK SULKOWSKI, MD
ABBOTT, BIPI, BMS, GILEAD, JANSSEN, MERCK, ROCHE, VERTEX
RESEARCH GRANT
ABBOTT, BIPI, BMS, GILEAD, JANSSEN, MERCK, NOVARTIS,
CONSULTANT/ADVISOR
PFIZER, VERTEX
CONSULTANT/ADVISOR
IAN FRANK, MD
GILEAD, JANSSEN, ABBVIE, SALIX
ADVISOR, HONORARIUM
GLAXOSMITHKLINE
RESEARCH GRANT
Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary,
royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest,
excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment,
management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on
advisory committees or review panels, board membership, and other activities from which remuneration is received or expected
DISCLOSURE OF UNAPPROVED USES OF PRODUCTS
PRESENTER NAME
PRODUCT
David L. Thomas, MD, MPH
DAA in development for HCV and/or in patients with HIV